Rationale for the administration of opiate antagonists in treating infantile autism
- PMID: 2872816
Item in Clipboard
Rationale for the administration of opiate antagonists in treating infantile autism
Am J Ment Defic.
1986 May.
Abstract
A rationale exists for clinical trials of opiate antagonists in at least some patients with pervasive developmental disorders. An abnormality in levels of an endogenous opioid ligand, which may be partially corrected by neuroleptics, has been reported in the plasma of some autistic patients. Moreover, data suggesting that opiate antagonism may improve faulty attention and diminish the frequency of self-injurious behavior were reviewed. Opiate antagonists may prove useful for those autistic patients with a profile of inattentiveness and self-injurious behavior. Also, these agents may act synergistically with neuroleptics.
Similar articles
-
Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior.Psychopharmacol Bull. 1989;25(4):556-63. Psychopharmacol Bull. 1989. PMID: 2698484 Review.
-
[Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].Encephale. 1993 Mar-Apr;19(2):95-102. Encephale. 1993. PMID: 8275903 Review. French.
-
[Opiate hypothesis of the origin of early childhood autism and sequelae for psychopharmacotherapy].Z Kinder Jugendpsychiatr. 1992 Sep;20(3):185-96. Z Kinder Jugendpsychiatr. 1992. PMID: 1329399 Review. German. No abstract available.
-
Use of atypical antipsychotics in the treatment of autistic disorder.Ann Pharmacother. 2007 Apr;41(4):626-34. doi: 10.1345/aph.1H527. Epub 2007 Mar 27. Ann Pharmacother. 2007. PMID: 17389666 Review.
-
Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians.Dev Med Child Neurol. 1995 Mar;37(3):239-45. doi: 10.1111/j.1469-8749.1995.tb11998.x. Dev Med Child Neurol. 1995. PMID: 7890130
Cited by
-
An urgent need for experimental animal model of autism in drug development.Ann Neurosci. 2015 Jan;22(1):44-9. doi: 10.5214/ans.0972.7531.220210. Ann Neurosci. 2015. PMID: 26124551 Free PMC article. Review.
-
High complement factor I activity in the plasma of children with autism spectrum disorders.Autism Res Treat. 2012;2012:868576. doi: 10.1155/2012/868576. Epub 2011 Oct 24. Autism Res Treat. 2012. PMID: 22928102 Free PMC article.
-
Brief report: a double-blind study of naltrexone in infantile autism.J Autism Dev Disord. 1992 Jun;22(2):309-19. doi: 10.1007/BF01058158. J Autism Dev Disord. 1992. PMID: 1345670 Clinical Trial. No abstract available.
-
Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children.J Autism Dev Disord. 1991 Jun;21(2):243-9. doi: 10.1007/BF02284764. J Autism Dev Disord. 1991. PMID: 1864831 No abstract available.
-
A case report of naltrexone treatment of self-injury and social withdrawal in autism.J Autism Dev Disord. 1990 Jun;20(2):169-76. doi: 10.1007/BF02284716. J Autism Dev Disord. 1990. PMID: 2189867 Clinical Trial.